½ÃÀ庸°í¼­
»óǰÄÚµå
1621816

¼¼°èÀÇ dPCR ¹× qPCR ½ÃÀå : Á¦Ç°, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚº° - ¿¹Ãø(2025-2030³â)

dPCR & qPCR Market by Product (Instruments, Reagents & Consumables, Software & Services), Application (Clinical Application, Forensic Applications, Research Application), End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 195 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

dPCR ¹× qPCR ½ÃÀåÀº 2023³â¿¡ 80¾ï 5,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 88¾ï 8,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç CAGR 10.23%·Î ¼ºÀåÇØ 2030³â¿¡´Â 159¾ï 4,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

µðÁöÅÐ PCR(dPCR)°ú Á¤·® PCR(qPCR)Àº DNA¿Í RNA¸¦ Á¤·®È­Çϱâ À§ÇØ »ý¹°ÇÐ ¹× ÀÇÇÐ ¿¬±¸¿¡¼­ ³Î¸® »ç¿ëµÇ´Â ÷´Ü ºÐÀÚ ±â¼úÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀÇ Çʿ伺Àº ³ôÀº Á¤È®µµ, ³ôÀº ¹Î°¨µµ ¹× ³·Àº ¿À¿° À§ÇèÀ¸·Î ÀÎÇØ ÀÓ»ó Áø´Ü, À¯ÀüÀÚ ¿¬±¸ ¹× ¹ýÀÇÇÐ ºÐ¼®¿¡ Àû¿ëÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀÇ ÃÖÁ¾ ¿ëµµ´Â Á¦¾à, »ý¸í°øÇÐ, ³ó¾÷, ȯ°æ ¿¬±¸ µî ´Ù¾çÇÑ ºÐ¾ß¿¡ °ÉÃÄ ÀÖÀ¸¸ç, º´¿øÃ¼ °ËÃâ, À¯ÀüÀÚ ¹ßÇö ºÐ¼®, À¯Àüü ¿¬±¸ µîÀÇ ºÐ¾ß¿¡¼­µµ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î´Â °¨¿°¼º ÁúȯÀÇ À¯Çà, À¯Àü¼º Áúȯ Áõ°¡, Á¤¹ÐÀÇ·áÀÇ º¸±Þ µîÀ» ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù. ÃÖ±Ù dPCR ½Ã½ºÅÛ°ú °°Àº ±â¼ú ¹ßÀüÀº ³ôÀº 󸮷®°ú ÀÚµ¿È­µÈ ó¸® ±â´ÉÀ» °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á Å« ÀáÀçÀû ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀ» Ȱ¿ëÇϱâ À§ÇØ ±â¾÷µéÀº ¿¬±¸±â°ü°úÀÇ Çù·ÂÀ» ÃËÁøÇϰí, ƯÁ¤ ¿ëµµ¿¡ ¸Â´Â »ç¿ëÇϱ⠽±°í ºñ¿ë È¿À²ÀûÀΠŰƮ °³¹ß¿¡ ÅõÀÚÇØ¾ß ÇÕ´Ï´Ù. ±×·¯³ª ³ôÀº Àåºñ ºñ¿ë, µ¥ÀÌÅÍ ºÐ¼®ÀÇ º¹À⼺, ÀáÀçÀû ÃÖÁ¾ »ç¿ëÀÚ(ƯÈ÷ ½ÅÈï Áö¿ª)ÀÇ ³·Àº ÀÎÁöµµ µîÀ¸·Î ÀÎÇØ ½ÃÀåÀº ÇѰ迡 Á÷¸éÇØ ÀÖ½À´Ï´Ù. Àü·«Àû °¡°Ý Ã¥Á¤ ¸ðµ¨°ú źźÇÑ ±³À° ÇÁ·Î±×·¥À» ÅëÇØ ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇÏ¸é ½ÃÀå ħÅõ¸¦ È®´ëÇÒ ¼ö ÀÖ½À´Ï´Ù. Çõ½Å°ú ¿¬±¸´Â Ä¡·á ¿µ¿ª¿¡¼­ dPCR°ú qPCRÀÇ À¯¿ë¼ºÀ» È®´ëÇϱâ À§ÇØ ½Ç½Ã°£ ÇöÀå Àû¿ëÀ» À§ÇÑ ÈÞ´ë¿ë ÅëÇÕ ½Ã½ºÅÛ °³¹ß, ºÐ¼®ÀÇ ´ÙÁßÈ­ ±â´É °­È­, Á¤È®µµ ¹× ¼Óµµ Çâ»ó¿¡ ÃÊÁ¡À» ¸ÂÃß¾î¾ß ÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀº ¿ªµ¿ÀûÀ̸ç, ÁÖ¿ä ±â¾÷µéÀÌ Çõ½ÅÀ» ÁÖµµÇÏ´Â °­·ÂÇÑ °æÀï ±¸µµ¸¦ Ư¡À¸·Î ÇÕ´Ï´Ù. ÀÌ ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§Çؼ­´Â Àü·«Àû Á¦ÈÞ¸¦ ¿ì¼±½ÃÇϰí, Â÷¼¼´ë ±â¼ú·Î Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇϰí, »õ·Î¿î ±ÔÁ¦¿Í Ç¥ÁØ¿¡ Àû±ØÀûÀ¸·Î ´ëÀÀÇÏ¿© »ý¸í°úÇÐ ¹× ³ó¾÷ ºÐ¾ßÀÇ ÁøÈ­ÇÏ´Â ¿ä±¸¸¦ ÃæÁ·½Ãų ¼ö ÀÖ´Â ¼Ö·ç¼ÇÀÌ µÉ ¼ö ÀÖµµ·Ï ³ë·ÂÇØ¾ß ÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 80¾ï 5,000¸¸ ´Þ·¯
ÃßÁ¤ ¿¬µµ(2024³â) 88¾ï 8,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 159¾ï 4,000¸¸ ´Þ·¯
CAGR(%) 10.23%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â dPCR ¹× qPCR ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

dPCR ¹× qPCR ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • °¨¿°º´ ¹× À¯Àü¼º ÁúȯÀÇ À¯º´·ü »ó½Â
    • °³ÀθÂÃãÇü ÀǷḦ È¿À²ÀûÀ¸·Î Á¦°øÇϱâ À§ÇÑ dPCR°ú qPCRÀÇ È°¿ë È®´ë
    • ¾ÈÀü°ú ¼Òºñ¸¦ º¸ÀåÇϱâ À§ÇÑ ½Äǰ °Ë»ç ÀýÂ÷ÀÇ Ã¤Åà Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • dPCR ¹× qPCR°ú °ü·ÃµÈ ³ôÀº ºñ¿ë
  • ½ÃÀå ±âȸ
    • PCR ±â¼úÀÇ ±â¼úÀû Áøº¸
    • ¼¼°è À¯ÀüüÇÐ ¿¬±¸ ÇÁ·ÎÁ§Æ®¿¡ ´ëÇÑ ÀÚ±Ý Áö¿ø È®´ë
  • ½ÃÀå °úÁ¦
    • dPCR ¹× qPCR ±â¼ú¿¡ µû¸¥ ±â¼úÀû ÇѰè¿Í µ¥ÀÌÅÍ ºÐ¼®ÀÇ º¹À⼺

Porter's Five Forces: dPCR ¹× qPCR ½ÃÀå Ž»öÀ» À§ÇÑ Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. PorterÀÇ Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : dPCR ¹× qPCR ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

PESTLE ºÐ¼® : dPCR ¹× qPCR ½ÃÀå¿¡¼­ÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº dPCR ¹× qPCR ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® dPCR ¹× qPCR ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

dPCR ¹× qPCR ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º dPCR ¹× qPCR ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â dPCR ¹× qPCR ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

dPCR ¹× qPCR ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× ±ÇÀå »çÇ×

dPCR ¹× qPCR ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå dPCR ¹× qPCR ½ÃÀå : Á¦Ç°º°

  • ±â±â
  • ½Ã¾à ¹× ¼Ò¸ðǰ
  • ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º

Á¦7Àå dPCR ¹× qPCR ½ÃÀå : ¿ëµµº°

  • ÀÓ»ó ÀÀ¿ë
    • Ç÷¾× °Ë»ç
    • Á¾¾çÇÐ °Ë»ç
    • º´¿øÃ¼ °Ë»ç
  • ¹ýÀÇÇÐ ¿ëµµ
  • ¿¬±¸ ¿ëµµ

Á¦8Àå dPCR ¹× qPCR ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • Çмú¿¬±¸±â°ü
  • °è¾à¿¬±¸±â°ü
  • º´¿ø ¹× °£È£ ¼­ºñ½º Á¦°ø¾÷ü
  • Á¦¾à ±â¾÷ ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ dPCR ¹× qPCR ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ dPCR ¹× qPCR ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ dPCR ¹× qPCR ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • 10x Genomics, Inc.
  • Abbott Laboratories
  • accela s.r.o.
  • Agilent Technologies, Inc.
  • Analytik Jena GmbH
  • Becton Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioMed Central Ltd
  • BioMerieux S.A.
  • Canopy Biosciences, LLC
  • Combinati Inc.
  • Danaher Corporation
  • F. Hoffman-La Roche Ltd.
  • GE Healthcare Inc.
  • JN Medsys Pte. Ltd.
  • Merck KGaA
  • PerkinElmer, Inc.
  • Pfizer Inc.
  • Promega Corporation
  • QIAGEN N.V. by Thermo Fisher Scientific, Inc.
  • Roche Holding AG
  • Siemens Healthineers AG
  • Stilla Technologies SA
  • Takara Bio Inc.
  • Vela Diagnostics
LSH 25.01.03

The dPCR & qPCR Market was valued at USD 8.05 billion in 2023, expected to reach USD 8.88 billion in 2024, and is projected to grow at a CAGR of 10.23%, to USD 15.94 billion by 2030.

Digital PCR (dPCR) and quantitative PCR (qPCR) are advanced molecular technologies used extensively in biological and medical research for quantifying DNA and RNA. The necessity for these technologies arises from their high precision, sensitivity, and reduction in risk of contamination, crucial for applications in clinical diagnostics, genetic research, and forensic analysis. The end-use scope of these technologies spans across diverse sectors including pharmaceuticals, biotechnology, agriculture, and environmental studies, whilst being pivotal in areas such as pathogen detection, gene expression analysis, and genomic studies. Key drivers influencing market growth include the increasing prevalence of infectious diseases, rising incidences of genetic disorders, and widespread adoption of precision medicine. Recent technological advancements, such as droplet-based dPCR systems, offer significant potential opportunities by enabling high-throughput and automated processing capabilities. To capitalize on these advancements, businesses should foster collaborations with research institutions and invest in developing user-friendly, cost-effective kits tailored for specific applications. However, the market faces limitations due to high equipment costs, complexity in data interpretation, and limited awareness among potential end-users, particularly in emerging regions. Addressing these challenges through strategic pricing models and robust training programs could expand market penetration. Innovation and research should focus on developing portable, integrated systems for real-time field applications, enhancing assay multiplexing capabilities, and improving accuracy and speed to broaden the utility of dPCR and qPCR in therapeutic areas. The market is dynamic, characterized by a strong competitive landscape with key players driving innovation. Firms looking to thrive in this market should prioritize strategic alliances, focus on expanding their product portfolio with next-gen technologies, and proactively adapt to emerging regulations and standards to ensure their solutions meet the evolving needs of the life sciences and agricultural sectors.

KEY MARKET STATISTICS
Base Year [2023] USD 8.05 billion
Estimated Year [2024] USD 8.88 billion
Forecast Year [2030] USD 15.94 billion
CAGR (%) 10.23%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving dPCR & qPCR Market

The dPCR & qPCR Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of infectious diseases and genetic disorders
    • Increasing usage of dPCR and qPCR for efficient delivery of personalized medicine
    • Improving adoption in food testing procedures to ensure safety and consumption
  • Market Restraints
    • High cost associated with dPCR and qPCR
  • Market Opportunities
    • Technological advancements in PCR technologies
    • Growing funding for genomics research projects worldwide
  • Market Challenges
    • Technical limitations and data analysis complexities associated with dPCR and qPCR techniques

Porter's Five Forces: A Strategic Tool for Navigating the dPCR & qPCR Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the dPCR & qPCR Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the dPCR & qPCR Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the dPCR & qPCR Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the dPCR & qPCR Market

A detailed market share analysis in the dPCR & qPCR Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the dPCR & qPCR Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the dPCR & qPCR Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the dPCR & qPCR Market

A strategic analysis of the dPCR & qPCR Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the dPCR & qPCR Market, highlighting leading vendors and their innovative profiles. These include 10x Genomics, Inc., Abbott Laboratories, accela s.r.o., Agilent Technologies, Inc., Analytik Jena GmbH, Becton Dickinson and Company, Bio-Rad Laboratories, Inc., BioMed Central Ltd, BioMerieux S.A., Canopy Biosciences, LLC, Combinati Inc., Danaher Corporation, F. Hoffman-La Roche Ltd., GE Healthcare Inc., JN Medsys Pte. Ltd., Merck KGaA, PerkinElmer, Inc., Pfizer Inc., Promega Corporation, QIAGEN N.V. by Thermo Fisher Scientific, Inc., Roche Holding AG, Siemens Healthineers AG, Stilla Technologies SA, Takara Bio Inc., and Vela Diagnostics.

Market Segmentation & Coverage

This research report categorizes the dPCR & qPCR Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Instruments, Reagents & Consumables, and Software & Services.
  • Based on Application, market is studied across Clinical Application, Forensic Applications, and Research Application. The Clinical Application is further studied across Blood Screening, Oncology Testing, and Pathogen Testing.
  • Based on End-User, market is studied across Academic Research & Institutes, Contract Research Organizations, Hospitals & Care Providers, and Pharmaceutical & Biotechnology Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of infectious diseases and genetic disorders
      • 5.1.1.2. Increasing usage of dPCR and qPCR for efficient delivery of personalized medicine
      • 5.1.1.3. Improving adoption in food testing procedures to ensure safety and consumption
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with dPCR and qPCR
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in PCR technologies
      • 5.1.3.2. Growing funding for genomics research projects worldwide
    • 5.1.4. Challenges
      • 5.1.4.1. Technical limitations and data analysis complexities associated with dPCR and qPCR techniques
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Expanding presence of sophisticated PCR instruments for rapid detection of genetic sequences
    • 5.2.2. Application: Utilization of dPCR and qPCR in clinical applications for infection monitoring and detection
    • 5.2.3. End-user: Rising focus of academic research and academic institutes toward PCR technologies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. dPCR & qPCR Market, by Product

  • 6.1. Introduction
  • 6.2. Instruments
  • 6.3. Reagents & Consumables
  • 6.4. Software & Services

7. dPCR & qPCR Market, by Application

  • 7.1. Introduction
  • 7.2. Clinical Application
    • 7.2.1. Blood Screening
    • 7.2.2. Oncology Testing
    • 7.2.3. Pathogen Testing
  • 7.3. Forensic Applications
  • 7.4. Research Application

8. dPCR & qPCR Market, by End-User

  • 8.1. Introduction
  • 8.2. Academic Research & Institutes
  • 8.3. Contract Research Organizations
  • 8.4. Hospitals & Care Providers
  • 8.5. Pharmaceutical & Biotechnology Companies

9. Americas dPCR & qPCR Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific dPCR & qPCR Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa dPCR & qPCR Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. QIAGEN Expands Range of Digital PCR Kits and Services for the Biopharma Industry
    • 12.3.2. Virax Biolabs Group Limited Has Entered into an Agreement for the Distribution of Marburg Virus PCR Testing Kits
    • 12.3.3. Thermo Fisher Scientific Launches New Digital PCR Automation Solution
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 10x Genomics, Inc.
  • 2. Abbott Laboratories
  • 3. accela s.r.o.
  • 4. Agilent Technologies, Inc.
  • 5. Analytik Jena GmbH
  • 6. Becton Dickinson and Company
  • 7. Bio-Rad Laboratories, Inc.
  • 8. BioMed Central Ltd
  • 9. BioMerieux S.A.
  • 10. Canopy Biosciences, LLC
  • 11. Combinati Inc.
  • 12. Danaher Corporation
  • 13. F. Hoffman-La Roche Ltd.
  • 14. GE Healthcare Inc.
  • 15. JN Medsys Pte. Ltd.
  • 16. Merck KGaA
  • 17. PerkinElmer, Inc.
  • 18. Pfizer Inc.
  • 19. Promega Corporation
  • 20. QIAGEN N.V. by Thermo Fisher Scientific, Inc.
  • 21. Roche Holding AG
  • 22. Siemens Healthineers AG
  • 23. Stilla Technologies SA
  • 24. Takara Bio Inc.
  • 25. Vela Diagnostics
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦